Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1?? subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.
Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1?? subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
